AstraZeneca share price forecast after earnings

AstraZeneca reported robust first-half financial results, with product sales up 8% to $26.67 billion and total revenue reaching $28 billion, exceeding median estimates, driven largely by its oncology and CVRM divisions. Despite this strong performance and an optimistic full-year forecast for high single-digit revenue growth, AZN stock remained steady, with technical analysis indicating a bearish flag pattern and potential downside. Strategically, the company pledged a $50 billion investment in the US by 2030, partly in response to potential tariff threats, as the US remains its largest revenue driver.

Analysis

AstraZeneca demonstrated strong fundamental performance in its first-half results, with total revenue reaching $28 billion, surpassing the median estimate of $27.5 billion. This growth was underpinned by an 8% increase in product sales, primarily driven by the Oncology division, which generated $11.95 billion, and the Cardiovascular, Renal, and Metabolism (CVRM) unit, which contributed $6.5 billion. Despite this robust performance and positive forward guidance for high single-digit revenue growth and low double-digit core EPS growth for the full year, the stock price has remained range-bound. This muted market reaction appears to be influenced by two key factors outlined in the report. Firstly, technical analysis points to a potential 'bearish flag' pattern, suggesting downside risk and market hesitation. Secondly, significant geopolitical risk exists due to the company's substantial exposure to the US market, which accounts for 43% of revenue ($11.9 billion), and the stated threat of potential import tariffs. The company's pledge to invest $50 billion in the US by 2030 is a strategic move to mitigate this risk, but investor caution persists.

Key Decisions for Investors

• Investors should weigh the company's strong fundamentals and positive earnings guidance against the cautionary technical indicators, such as the bearish flag pattern, which may signal near-term price consolidation or a potential pullback.
• Given that the US market constitutes 43% of AstraZeneca's revenue, monitoring US trade policy and election-related rhetoric regarding pharmaceutical tariffs is critical for assessing future risk, despite the company's strategic $50 billion investment pledge.
• Traders should closely watch the specified price levels, as a sustained move above the 11,000p resistance could signal a bullish breakout, whereas a drop below the 10,650p support level would validate the bearish technical view.